Quick Answer
IONIS PHARMACEUTICALS INC reported Cash and Equivalents of $372.26 million for fiscal year 2025.
IONIS PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $372.26M | +53.8% |
| 2024 | $242.08M | -39.4% |
| 2023 | $399.27M | +44.4% |
| 2022 | $276.47M | -68.2% |
| 2021 | $869.19M | +118.6% |
| 2020 | $397.66M | -41.8% |
| 2019 | $683.29M | +145.1% |
| 2018 | $278.82M | +115.1% |
| 2017 | $129.63M | +53.1% |
| 2016 | $84.69M | -34.2% |
| 2015 | $128.80M | -9.9% |
| 2014 | $143.00M | -10.6% |
| 2013 | $159.97M | +28.5% |
| 2012 | $124.48M | +90.1% |
| 2011 | $65.48M | -6.5% |
| 2010 | $70.05M | -33.4% |
| 2009 | $105.25M | -53.0% |
| 2008 | $223.99M | +61.6% |
| 2007 | $138.61M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $338.34M | +1.1% | +13.8% |
| June 30, 2025 | $297.30M | +1.1% | +12.5% |
| March 31, 2025 | $264.19M | -24.3% | +9.1% |
| December 31, 2024 | $242.08M | -39.4% | -27.7% |
| September 30, 2024 | $334.61M | -5.0% | +13.8% |
| June 30, 2024 | $293.99M | -30.8% | -15.7% |
| March 31, 2024 | $348.89M | +12.9% | -12.6% |
| December 31, 2023 | $399.27M | +44.4% | +13.4% |
- IONIS PHARMACEUTICALS INC showed an increase of +53.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2007–2025 period, IONIS PHARMACEUTICALS INC’s cash and equivalents has grown by 168.6% (from $138.61 million to $372.26 million).
- The most recent figure is from IONIS PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: